Chronic myeloid leukemia: the latest progress and future directions

VernacularTitle:慢性粒细胞白血病：最新研究进展和未来发展方向
Author: Xudong LI ¹ ; Yanli ZHANG ; Yongping SONG
Author Information

1. 郑州大学第一附属医院血液科，郑州　450052
Keywords: Chronic myeloid leukemia; Tyrosine kinase inhibitors; Treatment
From: Journal of Leukemia & Lymphoma 2023;32(2):74-78
CountryChina
Language:Chinese
Abstract: Chronic myeloid leukemia (CML) is a malignant hematological disease driven by BCR-ABL fusion protein. The emergence of tyrosine kinase inhibitor (TKI) targeting BCR-ABL has completely changed the treatment pattern of CML. From the approval of the first generation TKI imatinib in 2001 to the emergence of the fourth generation TKI drugs, CML patients have benefited a lot from it. But even so, many CML patients suffer treatment failure due to drug resistance, relapse after drug withdrawal or disease progression, some patients therefore are difficult to obtain long-term remission and still need multi-line TKI treatment. The research and development of new drugs covering more mutation lineages, more optimized treatment strategies and drug withdrawal-related research are still the focus of CML treatment. This article introduces the research progress of CML reported on the 64th American Society of Hematology annual meeting.